The Trump administration has officially authorized a new trade policy imposing tariffs of up to 100% on certain imported patented medicines. This aggressive maneuver is designed to pressure global drugmakers to move their manufacturing operations to the United States. The levy specifically targets drugs made in countries that do not have existing tariff agreements with the U.S. or by companies that lack "most-favored-nation" pricing agreements with the administration. 

While the baseline tariff is set at 100%, the White House has included several caveats and exemptions. Major economies that have negotiated deals with the U.S., such as the European Union, Japan, and South Korea, will see their tariffs capped at 15%. Furthermore, companies that commit to manufacturing within the U.S. or agree to specific pricing models can see their import rates fall as low as 0%. 

The announcement has triggered a wave of concern among healthcare providers and international trade partners. Critics argue that these barriers could lead to increased drug prices for American consumers in the short term, while supporters view it as a necessary step for national security and domestic industrial growth. Implementation will be phased, with duties for larger companies taking effect in 120 days and smaller manufacturers granted a 180-day window.